Outlook Therapeutics FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million

Reuters12-19 21:05

Outlook <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million

Outlook Therapeutics Inc. reported financial results for the full year ended September 30, 2025. The company recorded revenue of USD 1.4 million for the period. Net loss attributable to common stockholders was USD 62.4 million, or USD 1.79 per basic and diluted share. As of September 30, 2025, cash and cash equivalents stood at USD 8.1 million. Gross profit for the year was negatively affected by increased reserves for short-dated inventory included in original shipments to the UK in June 2025. Overall expenses for the fiscal year were USD 4.6 million lower than the previous year, primarily due to a reduction in research and development expenses following the completion of the NORSE Eight clinical trial in fiscal 2024. This decrease was partially offset by higher selling, general, and administrative expenses related to the launch of LYTENAVA in Europe in June 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604952-en) on December 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592625211?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592625211","market":"nz","top_or_hot":-1,"title":"Outlook Therapeutics FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Outlook Therapeutics Inc. reported financial results for the full year ended September 30, 2025. The company recorded revenue of USD 1.4 million for the period. Net loss attributable to common stockholders was USD 62.4 million, or USD 1.79 per basic and diluted share. As of September 30, 2025, cash and cash equivalents stood at USD 8.1 million. Gross profit for the year was negatively affected by increased reserves for short-dated inventory included in original shipments to the UK in June 2025. Overall expenses for the fiscal year were USD 4.6 million lower than the previous year, primarily due to a reduction in research and development expenses following the completion of the NORSE Eight clinical trial in fiscal 2024. This decrease was partially offset by higher selling, general, and administrative expenses related to the launch of LYTENAVA in Europe in June 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604952-en) on December 19, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outlook Therapeutics FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutlook Therapeutics FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-19 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Outlook Therapeutics Inc. reported financial results for the full year ended September 30, 2025. The company recorded revenue of USD 1.4 million for the period. Net loss attributable to common stockholders was USD 62.4 million, or USD 1.79 per basic and diluted share. As of September 30, 2025, cash and cash equivalents stood at USD 8.1 million. Gross profit for the year was negatively affected by increased reserves for short-dated inventory included in original shipments to the UK in June 2025. Overall expenses for the fiscal year were USD 4.6 million lower than the previous year, primarily due to a reduction in research and development expenses following the completion of the NORSE Eight clinical trial in fiscal 2024. This decrease was partially offset by higher selling, general, and administrative expenses related to the launch of LYTENAVA in Europe in June 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604952-en) on December 19, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLc4fhc:1","article_id":"2592625211","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592625211","pubTimestamp":1766149517,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Outlook Therapeutics Inc. reported financial results for the full year ended September 30, 2025. The company recorded revenue of USD 1.4 million for the period. Net loss attributable to common stockholders was USD 62.4 million, or USD 1.79 per basic and diluted share. As of September 30, 2025, cash and cash equivalents stood at USD 8.1 million. Gross profit for the year was negatively affected by increased reserves for short-dated inventory included in original shipments to the UK in June 2025. Overall expenses for the fiscal year were USD 4.6 million lower than the previous year, primarily due to a reduction in research and development expenses following the completion of the NORSE Eight clinical trial in fiscal 2024. This decrease was partially offset by higher selling, general, and administrative expenses related to the launch of LYTENAVA in Europe in June 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","OTLK":"Outlook Therapeutics, Inc."},"translate_title":"Outlook Therapeutics 2025财年净亏损收窄至6240万美元，营收达140万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"OTLK":0.9},"content_text":"Outlook Therapeutics FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million\n    \n\n        Outlook Therapeutics Inc. reported financial results for the full year ended September 30, 2025. The company recorded revenue of USD 1.4 million for the period. Net loss attributable to common stockholders was USD 62.4 million, or USD 1.79 per basic and diluted share. As of September 30, 2025, cash and cash equivalents stood at USD 8.1 million. Gross profit for the year was negatively affected by increased reserves for short-dated inventory included in original shipments to the UK in June 2025. Overall expenses for the fiscal year were USD 4.6 million lower than the previous year, primarily due to a reduction in research and development expenses following the completion of the NORSE Eight clinical trial in fiscal 2024. This decrease was partially offset by higher selling, general, and administrative expenses related to the launch of LYTENAVA in Europe in June 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9604952-en) on December 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592625211","isCrawlerRequest":true}